MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
71.21
+0.68
+0.96%
Pre Market: 71.16 -0.05 -0.07% 04:20 10/05 EDT
OPEN
70.63
PREV CLOSE
70.53
HIGH
71.91
LOW
70.10
VOLUME
6
TURNOVER
--
52 WEEK HIGH
80.59
52 WEEK LOW
52.01
MARKET CAP
152.05B
P/E (TTM)
23.66
1D
5D
1M
3M
1Y
5Y
HHS change to Medicare payments for biosimilars aims to spur uptake
A temporary increase in payments from Medicare for certain biosimilar medications is designed to boost uptake of cheaper versions of high-priced biologic drugs. The increase, which went into effect Monday, is a provision of the Inf...
Seekingalpha · 17h ago
Bristol in collaboration pact with tiny biotech SyntheX on targeted protein degraders
Bristol-Myers Squibb (NYSE:BMY) and privately held bi...
Seekingalpha · 19h ago
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
Benzinga · 21h ago
Exelixis expands cancer clinical trial collaboration & supply pact with Bristol-Myers
Exelixis (NASDAQ:EXEL) on Tuesday said it would include the use of...
Seekingalpha · 23h ago
BRIEF-Synthex And Bristol Myers Squibb Enter Into A Research Collaboration To Discover And Develop Targeted Protein Degradation (Tpd) Therapeutics
BRIEF-Synthex And Bristol Myers Squibb Enter Into A Research Collaboration To Discover And Develop Targeted Protein Degradation (Tpd) Therapeutics
Reuters · 23h ago
Autolus stock rises on Bristol Myers contract for use of safety switch with cell therapies
Bristol Myers Squibb (NYSE:BMY) <a href="https://seekingalp...
Seekingalpha · 23h ago
Exelixis Expands Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Include Fixed-Dose Combination Of Nivolumab And Relatlimab In Combination With XL092 In Phase 1b STELLAR-002 Trial
Agreement enables evaluation of XL092 in combination with an additional immune checkpoint inhibitor — ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) today announced the expansion of its June 2021
Benzinga · 1d ago
Exelixis, Bristol-Myers Squibb Expand Clinical Trial Collaboration in Solid Tumors Study
Exelixis, Bristol-Myers Squibb Expand Clinical Trial Collaboration in Solid Tumors Study
MT Newswires · 1d ago
More
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.